Guangdong Hicicare Science (Hicicare) and Zylox-Tonbridge Medical Technology (Zylox-Tonbridge) have formed a strategic partnership aimed at facilitating the commercialisation of vascular guidewire products under a co-branded label in China.

The partnership’s goal is to bring innovative vascular access solutions to Chinese physicians and patients by launching products for neuro and peripheral-vascular interventional device market segments.

Zylox-Tonbridge chairman and CEO Dr Jonathon Zhong Zhao said: “The strategic partnership with Hicicare will expand our portfolio and represents the latest step in our journey towards creating a leading medical device platform for vascular interventions in China.”

As part of the collaboration, Zylox-Tonbridge’s peripheral vascular business unit Zylox Medical intends to introduce its Zylox-Hicicare Guidewire family of products to cater to the diverse requirements of clinical clients in peripheral-vascular interventional procedures.

These procedures include imaging diagnosis, as well as the treatment of conditions such as stenosis, complete occlusion lesions and moderate to severe calcification.

The company’s Tonbridge Medical neurovascular division partnered with Hicicare to launch the Beidou series micro guide wires, which offer precise guidance and are suitable for treating both ischemic and haemorrhagic strokes.

Hicicare general manager Liu Yitong said: “We decided to partner with Zylox-Tonbridge as we are pursuing a shared vision. I believe that the strong alliance reinforces our commitment to shaping a better future for all and lays a solid foundation for our future growth. We look forward to working closely with Zylox-Tonbridge to capitalize on the opportunities for exciting and sustainable growth.”